Coronary artery bypass surgery perioperative management of myocardial dysfunction: Difference between revisions
Esther Lee (talk | contribs) (Created page with "__NOTOC__ {{Coronary artery bypass surgery}} {{CMG}}; {{AOEIC}} {{VK}} ==ACCF/AHA Guidelines for Perioperative Myocardial Dysfunction== {{cquote| ===[[ACC AHA guidelines clas...") |
Esther Lee (talk | contribs) |
||
Line 4: | Line 4: | ||
==ACCF/AHA Guidelines for Perioperative Myocardial Dysfunction== | ==ACCF/AHA Guidelines for Perioperative Myocardial Dysfunction== | ||
'''2.''' Measurement of biomarkers of myonecrosis (eg, creatine kinase-MB, troponin) is reasonable in the first 24 hours after CABG.200 (Level of Evidence: B) | {|class="wikitable" | ||
|- | |||
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen"| | |||
<nowiki>"</nowiki>'''1.''' In the absence of severe, symptomatic aorto-iliac occlusive disease or PAD, the insertion of an intraaortic balloon is reasonable to reduce mortality rate in CABG patients who are considered to be at high risk (eg, those who are undergoing reoperation or have LVEF <30% or left main CAD).1021–1026 (Level of Evidence: B)<nowiki>"</nowiki> | |||
|- | |||
| bgcolor="LightGreen"| | |||
<nowiki>"</nowiki>'''2.''' Measurement of biomarkers of myonecrosis (eg, creatine kinase-MB, troponin) is reasonable in the first 24 hours after CABG.200 (Level of Evidence: B)<nowiki>"</nowiki> | |||
|} | |||
==Guidelines Resources== | ==Guidelines Resources== |
Revision as of 15:20, 3 October 2012
Coronary Artery Bypass Surgery Microchapters | |
Pathophysiology | |
---|---|
Diagnosis | |
Treatment | |
Perioperative Monitoring | |
Surgical Procedure | |
Special Scenarios | |
Coronary artery bypass surgery perioperative management of myocardial dysfunction On the Web | |
FDA on Coronary artery bypass surgery perioperative management of myocardial dysfunction | |
CDC on Coronary artery bypass surgery perioperative management of myocardial dysfunction | |
Coronary artery bypass surgery perioperative management of myocardial dysfunction in the news | |
Blogs on Coronary artery bypass surgery perioperative management of myocardial dysfunction|- |
|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Varun Kumar, M.B.B.S. [2]
ACCF/AHA Guidelines for Perioperative Myocardial Dysfunction
Class I |
"1. In the absence of severe, symptomatic aorto-iliac occlusive disease or PAD, the insertion of an intraaortic balloon is reasonable to reduce mortality rate in CABG patients who are considered to be at high risk (eg, those who are undergoing reoperation or have LVEF <30% or left main CAD).1021–1026 (Level of Evidence: B)" |
"2. Measurement of biomarkers of myonecrosis (eg, creatine kinase-MB, troponin) is reasonable in the first 24 hours after CABG.200 (Level of Evidence: B)" |
Guidelines Resources
- 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery : A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[1]
References
- ↑ Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG; et al. (2011). "2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0b013e31823c074e. PMID 22064599.